Crinetics Pharmaceuticals, Inc.
DE ˙ DB ˙ US22663K1079
27,79 € ↑0,30 (1,09%)
2026-06-04
DEL PRIS
SecurityDE:6Z4 / Crinetics Pharmaceuticals, Inc.
InstitutionMorgan Stanley
Latest Disclosed Ownership919,686 shares
Latest Disclosed Value $ 33,403,019
Morgan Stanley reports 19.62% increase in ownership of 6Z4 / Crinetics Pharmaceuticals, Inc.

On May 15, 2026 - Morgan Stanley filed a 13F-HR form disclosing ownership of 919,686 shares of Crinetics Pharmaceuticals, Inc. (DE:6Z4) valued at $27,222,706 USD as of March 31, 2026. The entity filed a previous 13F-HR/A on May 27, 2026 disclosing 768,826 shares of Crinetics Pharmaceuticals, Inc.. This represents a change in shares of 19.62% during the quarter. The current value of the position is $25,558,074 USD.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date		 Effective
Date		Form Security Class ID Avg Price
Paid (Est)		 Reported
Shares		 ΔShares ΔShares
(%)		 Reported
Value
(x1000)		 ΔValue
(%)		 Alloc
(%)		 ΔAlloc ΔAlloc (%) Cost Basis
(x1000)		 Unrealized
Gain/Loss
(x1000)
2026-05-15 2026-03-31 13F CRINETICS PHARMACEUTICALS IN COM 22663K107 919,686 150,860 19.62 33,403 -6.66 0.0020
2026-05-27 2025-12-31 13F/A-1 CRINETICS PHARMACEUTICALS IN COM 22663K107 768,826 86,692 12.71 35,789 25.97 0.0021
2026-02-13 2025-12-31 13F CRINETICS PHARMACEUTICALS IN COM 22663K107 768,826 86,692 35,789 0.0021
2026-05-27 2025-09-30 13F/A-1 CRINETICS PHARMACEUTICALS IN COM 22663K107 682,134 -77,888 -10.25 28,411 29.98 0.0017
2025-11-14 2025-09-30 13F CRINETICS PHARMACEUTICALS IN COM 22663K107 682,134 -77,888 28,411 0.0017
2025-08-15 2025-06-30 13F CRINETICS PHARMACEUTICALS IN COM 22663K107 760,022 245,338 47.67 21,858 26.62 0.0014
2025-05-15 2025-03-31 13F CRINETICS PHARMACEUTICALS IN COM 22663K107 514,684 9,644 1.91 17,263 -33.15 0.0012
2025-05-15 2024-12-31 13F/A-1 CRINETICS PHARMACEUTICALS IN COM 22663K107 505,040 -160,559 -24.12 25,823 -24.08 0.0018
2025-02-14 2024-12-31 13F CRINETICS PHARMACEUTICALS IN COM 22663K107 505,040 -160,559 25,823 0.0018
2025-05-14 2024-09-30 13F/A-2 CRINETICS PHARMACEUTICALS IN COM 22663K107 665,599 -173,026 -20.63 34,012 -9.45 0.0025
2025-02-14 2024-09-30 13F/A-1 CRINETICS PHARMACEUTICALS IN COM 22663K107 665,599 -173,026 34,012 0.0025
2024-11-14 2024-09-30 13F CRINETICS PHARMACEUTICALS IN COM 22663K107 665,599 -173,026 34,012 0.0025
2025-05-14 2024-06-30 13F/A-2 CRINETICS PHARMACEUTICALS IN COM 22663K107 838,625 226,425 36.99 37,562 31.07 0.0029
2024-10-17 2024-06-30 13F/A-1 CRINETICS PHARMACEUTICALS IN COM 22663K107 838,625 226,425 37,562 0.0029
2024-08-14 2024-06-30 13F CRINETICS PHARMACEUTICALS IN COM 22663K107 838,625 226,425 37,562 0.0029
2024-10-17 2024-03-31 13F/A-2 CRINETICS PHARMACEUTICALS IN COM 22663K107 612,200 -36,051 -5.56 28,657 24.25 0.0023
2024-08-16 2024-03-31 13F/A-1 CRINETICS PHARMACEUTICALS IN COM 22663K107 612,200 -36,051 28,657 0.0003
2024-05-15 2024-03-31 13F CRINETICS PHARMACEUTICALS IN COM 22663K107 612,200 -36,051 28,657 0.0023
2024-08-16 2023-12-31 13F/A-1 CRINETICS PHARMACEUTICALS IN COM 22663K107 648,251 136,930 26.78 23,065 51.68 0.0020
2024-02-13 2023-12-31 13F CRINETICS PHARMACEUTICALS IN COM 22663K107 648,251 136,930 23,065 0.0020
2023-11-15 2023-09-30 13F CRINETICS PHARMACEUTICALS IN COM 22663K107 511,321 -234,838 -31.47 15,207 13.10 0.0015
2023-08-14 2023-06-30 13F CRINETICS PHARMACEUTICALS IN COM 22663K107 746,159 93,243 14.28 13,446 28.23 0.0013
2023-05-15 2023-03-31 13F CRINETICS PHARMACEUTICALS IN COM 22663K107 652,916 500,328 327.89 10,486 275.54 0.0011
2023-02-14 2022-12-31 13F CRINETICS PHARMACEUTICALS IN COM 22663K107 152,588 50,556 49.55 2,792 39.32 0.0003
2022-11-14 2022-09-30 13F CRINETICS PHARMACEUTICALS IN COM 22663K107 102,032 -37,584 -26.92 2,004 -23.07 0.0003
2022-10-27 2022-06-30 13F/A-1 CRINETICS PHARMACEUTICALS IN COM 22663K107 139,616 44,326 46.52 2,605 24.52 0.0003
2022-08-15 2022-06-30 13F CRINETICS PHARMACEUTICALS IN COM 22663K107 139,616 44,326 2,605 0.0001
2022-10-27 2022-03-31 13F/A-1 CRINETICS PHARMACEUTICALS IN COM 22663K107 95,290 57,312 150.91 2,092 93.88 0.0003
2022-05-13 2022-03-31 13F CRINETICS PHARMACEUTICALS IN COM 22663K107 95,290 57,312 2,092 0.0003
2022-02-14 2021-12-31 13F CRINETICS PHARMACEUTICALS IN COM 22663K107 37,978 -30,976 -44.92 1,079 -25.64 0.0001
2021-11-15 2021-09-30 13F CRINETICS PHARMACEUTICALS IN COM 22663K107 68,954 -113,043 -62.11 1,451 -57.70 0.0002
2021-08-23 2021-06-30 13F/A-1 CRINETICS PHARMACEUTICALS IN COM 22663K107 181,997 -18,756 -9.34 3,430 11.80 0.0005
2021-08-16 2021-06-30 13F CRINETICS PHARMACEUTICALS IN COM 22663K107 181,997 -18,756 3,430 0.0001
2021-05-17 2021-03-31 13F CRINETICS PHARMACEUTICALS IN COM 22663K107 200,753 15,011 8.08 3,068 17.10 0.0005
2021-02-16 2020-12-31 13F CRINETICS PHARMACEUTICALS IN COM 22663K107 185,742 145,036 356.30 2,620 310.66 0.0004
2020-11-13 2020-09-30 13F CRINETICS PHARMACEUTICALS IN COM 22663K107 40,706 -173,115 -80.96 638 -82.96 0.0001
2020-08-14 2020-06-30 13F CRINETICS PHARMACEUTICALS IN COM 22663K107 213,821 211,570 9,398.93 3,745 10,914.71 0.0008
2020-05-26 2020-03-31 13F/A-1 CRINETICS PHARMACEUTICALS IN COM 22663K107 2,251 -15,156 -87.07 34 -92.22 0.0000
2020-05-15 2020-03-31 13F CRINETICS PHARMACEUTICALS IN COM 22663K107 2,251 -15,156 34 2.6119
2020-02-14 2019-12-31 13F CRINETICS PHARMACEUTICALS IN COM 22663K107 17,407 -131 -0.75 437 65.53 0.0001
2019-11-14 2019-09-30 13F CRINETICS PHARMACEUTICALS IN COM 22663K107 17,538 16,249 1,260.59 264 725.00 0.0001
2019-08-14 2019-06-30 13F CRINETICS PHARMACEUTICALS IN COM 22663K107 1,289 -1,693 -56.77 32 -52.24 0.0000
2019-05-15 2019-03-31 13F CRINETICS PHARMACEUTICALS IN COM 22663K107 2,982 -9,201 -75.52 67 -81.64 0.0000
2019-02-14 2018-12-31 13F CRINETICS PHARMACEUTICALS IN COM 22663K107 12,183 -153 -1.24 365 3.40 0.0001
2019-04-23 2018-09-30 13F/A-2 CRINETICS PHARMACEUTICALS IN COM 22663K107 12,336 12,336 353 0.0001
2018-11-20 2018-09-30 13F/A-1 CRINETICS PHARMACEUTICALS IN COM 22663K107 12,336 0 353 0.0001
2018-11-14 2018-09-30 13F CRINETICS PHARMACEUTICALS IN COM 22663K107 12,336 353 0.0001
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.